Biological
Live Attenuated Influenza Vaccine clinical trials
- studies test it
- 18
- open now
- 2
- in phase 3
- 1
- first study started
- 2010
Keep track of what changes. Save the Live Attenuated Influenza Vaccine studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
17 studies that test it; most in 2018 (3); 1 more planned to start later
| Year | Studies |
|---|---|
| 2010 | 2 |
| 2011 | 1 |
| 2012 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2018 | 3 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 2 |
| 2022 | 1 |
| 2024 | 1 |
| 2025 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 2
- Phase 2
- 1
- Phase 3
- 1
- Phase 4
- 11
- No phase
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 3 · Other 15
Changchun BCHT Biotechnology Co. (3) · Imperial College London (2) · University of Rochester (2) · The University of Hong Kong (1) · University of Alabama at Birmingham (1) · Emory University (1) · Emily McDonald (1) · Stanford University (1)
Often tested with
Tested in the same studies.
Influenza Vaccines (2)
Studies
Open first, then newest update. How each study uses Live Attenuated Influenza Vaccine is read from its arms, and is right about nine times in ten.
Testing it · 18
- Intranasal LAIV Mucosal Immunity ExaminationNot yet recruitingPhase 4University of Maryland, BaltimoreNCT07093281Written as Live Attenuated Influenza Vaccine
- Woodsmoke Exposure, Influenza Infection, and Nasal ImmunityRecruitingPhase 4University of North Carolina, Chapel HillNCT06841913Written as LAIV nasal vaccine is chosen as a model viral infection
- Live Attenuated Influenza Vaccine as a Nasal Model for Influenza InfectionCompletedPhase 4University of Alabama at BirminghamNCT04164212Written as Flumist Quadrivalent Nasal Product
- The Dynamics of the Immune Responses to Repeat Influenza Vaccination Exposures (DRIVE III) StudyActive, not recruitingPhase 4The University of Hong KongNCT07240922Written as Live attenuated influenza vaccine
- Revealing Protective Immunity to Influenza Using Systems ImmunologyCompletedPhase 4Emory UniversityNCT06501963Written as Live Attenuated Influenza Vaccine
- Use of Wearable Sensors for Early Detection and Tracking of Viral Respiratory Tract InfectionsCompletedNot applicableEmily McDonaldNCT05290792Written as Administration of FluMist (Live Attenuated Influenza Vaccine)
- The Effects of Attenuated Versus Inactivated Flu Vaccine in Twin SetsCompletedPhase 1Stanford UniversityNCT03898986Written as Live attenuated influenza vaccine (LAIV4)
- Assessment of Viral Shedding Week Following Administration of Live Attenuated Influenza Vaccine in ChildrenCompletedPhase 4Imperial College LondonNCT03735147Written as Live attenuated influenza vaccine (LAIV)
- The Safety and Immunogenicity Evaluation of Live Attenuated Influenza VaccineStatus unknownPhase 2Changchun BCHT Biotechnology Co.NCT05284851Written as Live Attenuated Influenza Vaccine(non freeze-dried)
- Nasal and Systemic Immune Responses to Nasal Influenza VaccineCompletedNot applicableImperial College Healthcare NHS TrustNCT04110366Written as Live attenuated influenza vaccine
- The Safety and Immunogenicity Evaluation of Live Attenuated Influenza VaccineStatus unknownPhase 1Changchun BCHT Biotechnology Co.NCT05056519Written as Live Attenuated Influenza Vaccine
- Safety of LAIV4 in Children With AsthmaCompletedPhase 4Vanderbilt University Medical CenterNCT03600428Written as Live Attenuated Influenza Vaccine (LAIV)
- Evaluating Immune Response to Seasonal FluMist in Healthy AdultsTerminatedNot applicableNational Center for Occupational Health and Infection ControlNCT01673425Written as Live Attenuated Influenza Vaccine
- Efficacy & Safety of Nasal Influenza Immunisation in ChildrenCompletedPhase 4Imperial College LondonNCT02549365Written as Live attenuated influenza vaccine
- Live Attenuated Influenza Vaccine (LAIV) Versus Trivalent Inactivated Influenza Vaccine in Healthy Adults 18-49 YearsCompletedPhase 4St. Louis UniversityNCT03101462Written as Live Attenuated Influenza Vaccine
- A Trial on the Efficacy, Safety and Immunogenicity of Live-Attenuated Influenza Vaccine (LAIV)CompletedPhase 3Changchun BCHT Biotechnology Co.NCT02964065Written as Live-Attenuated influenza Vaccine(LAIV)
- Effect of Age and Prior Immunity to Response to Seasonal Influenza Vaccines in ChildrenCompletedPhase 4University of RochesterNCT01246999Written as Live attenuated Influenza vaccine
- Study of Live, Attenuated Influenza Vaccination in Preterm and Full-Term InfantsTerminatedPhase 4University of RochesterNCT01194297Written as Live attenuated influenza vaccine